SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Emcure Pharmaceuticals informs about change in management

05 May 2026 Evaluate
Pursuant to Regulation 30 of the SEBI Listing Regulations and based on the recommendation of the Nomination and Remuneration Committee, Emcure Pharmaceuticals has informed that the Board of Directors of the Company at their meeting held today i.e. Tuesday, May 05, 2026, has approved the re-appointment of the following Directors, subject to approval of shareholders: 1. Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the Company for a further period of 1 (One) year commencing from August 28, 2026; 2. Satish Mehta (DIN: 00118691) as the Managing Director of the Company, for a further period of 5 (Five) years with effective from April 01, 2027. Dr. Mukund Gurjar and Satish Mehta are not debarred from holding the office of a Director by virtue of any Securities and Exchange Board of India (‘SEBI’) SEBI order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and that they are not related to any Director(s) or Key Managerial Personnel(s) of the Company. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are enclosed. The meeting of the Board of Directors of the Company commenced at 12.42 pm (IST) and concluded at 2.00 pm (IST).

The above information is a part of company’s filings submitted to BSE.

Emcure Pharma Share Price

1691.45 -93.70 (-5.25%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×